Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy. Article uri icon

Overview

publication date

  • October 10, 2020

Research

keywords

  • Hydroxamic Acids
  • Myelodysplastic Syndromes

Identity

Scopus Document Identifier

  • 85092408417

Digital Object Identifier (DOI)

  • 10.1080/10428194.2020.1832674

PubMed ID

  • 33043735

Additional Document Info

volume

  • 62

issue

  • 2